2020

The meeting “Global Burden, Diagnosis, and Adjunctive Therapies of Sepsis and COVID-19” will be available via livestream today, March 16, at 5:00 pm CET Adrenomed recently announced positive topline data from its AdrenOSS-2 Phase II

Adrecizumab, given on top of standard of care, was well tolerated and showed a favorable safety profile Adrecizumab demonstrates a positive trend on survival AdrenOSS-2 is a biomarker-guided (sphingotest bio-ADM®[1]) trial in sepsis Mode of